Hematopoietic growth factors and acute leukemia

  • Jacob M. Rowe
  • Jane L. Liesveld
Part of the Cancer Treatment and Research book series (CTAR, volume 99)


The hematopoietic growth factors are glycoproteins that can be produced by recombinant DNA technology. They have many potential clinical uses in acute leukemia, and these will be discussed in this chapter. Several areas have been explored extensively, and many data are available from clinical trials. Other areas are of potential interest but have a paucity of clinical information. The past decade has seen major strides in the development and clinical application of cytokines in acute leukemia, and it is expected that this trend will continue over the next decade as further areas are explored and results of clinical trials mature to enable us to determine the precise role of cytokines in the clinical setting.


Acute Myeloid Leukemia Acute Leukemia Acute Myelogenous Leukemia Stem Cell Factor Chronic Granulomatous Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Larson RA, Linker CA, Kodge RK, et al. 1994. Granulocyte colony stimulating factor (filgrastim) reduces the time to neutrophil recovery in adults with acute lymphoblastic leukemia receiving intensive remission induction chemotherapy: CALGB Study 9111. Proc Am Soc Clin Oncol 13:305a. (abstract)Google Scholar
  2. 2.
    Ohno R, Tomonaga M, Kobayashi T. 1990. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323.Google Scholar
  3. 3.
    Ottmann OG, Hoelzer D, Gracien E, et al. 1993. Concomitant R-met HuG-CSF (filgrastim) and intensive chemoradiotherapy as induction treatment in adult ALL: a randomized multi-center phase III trial. Blood 82(Suppl 1):193a. (abstract)Google Scholar
  4. 4.
    Lowenberg B, Touw IP. 1993. Hematopoietic growth factors and their receptors in acute leukemia. Blood 81:281–292.PubMedGoogle Scholar
  5. 5.
    Visani G, Manfrio S. 1995. G-CSF in the biology and treatment of acute myeloid leukemias. Leuk Lymphoma 18:423–428.PubMedCrossRefGoogle Scholar
  6. 6.
    Yuo A, Kitagawa S, Iki S, Yagisawa M, Inuo EK, Mimuar T, Minoda S, Hanazono Y, Hirai H, Urabe A. 1995. Tyrosine phosphorylation of vav protooncogene product in primary human myelogenous leukemic cells stimulated by granulocyte colony-stimulating factor. Biochem Biophys Res Commun 211:677–685.PubMedCrossRefGoogle Scholar
  7. 7.
    Faussat-Suberville AM, Marie JP, Delmer A, Cadiou M, Zittoun R. 1993. In vitro effect of rGM-CSF on proliferation and maturation of leukemic cells from patients with acute myelogenous leukemia. Leuk Lymphoma 11:99–104.PubMedCrossRefGoogle Scholar
  8. 8.
    Hu JP, Cesano A, Santoli D, Clark SC, Hoang T. 1993. Effects of interleukin-11 on the proliferation and cell cycle status of myeloid leukemic cells. Blood 81:1586–1592.PubMedGoogle Scholar
  9. 9.
    Broudy VC, Smith FO, Lin N, Zsebo KN, Egrie J, Bernstein ID. 1992. Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. Blood 80:60–67.PubMedGoogle Scholar
  10. 10.
    Caceres-Cortes J, Rajotte D, Dumouchel J, Haddad P, Hoang T. 1994. Product of the steel locus suppresses apoptosis in hemopoietic cells. Comparison with pathways activated by granulocyte macrophage colony-stimulating factor. J Biol Chem 269:12084–12091.PubMedGoogle Scholar
  11. 11.
    Kubota A, Okamura S, Shimoda K, Harada M, Niho Y. 1994. The c-kit molecule and the surface immunophenotype of human acute leukemia. Leuk Lymphoma 14:421–428.PubMedCrossRefGoogle Scholar
  12. 12.
    Matsumura I, Kanakura Y, Ikeda H, Ishikawa J, Yoshida H, Horikawa Y, Nishiura T, Tahara T, Kato T, Miyazaki H, Matsuzawa Y. 1996. Coexpression of thrombopoietin and c-mpl genes in human acute myeloblastic leukemia cells. Leukemia 10:91–94.PubMedGoogle Scholar
  13. 13.
    Matsumura I, Kanakura Y, Kato T, Ikeda H, Horikawa Y, Ishikawa J, Katayama H, Nishiura T, Tomiyama Y, Miyazaki, Matsuzawa Y. 1996. The biologic properties of recombinanat human thrompotoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells. Blood 88:3074–3082.PubMedGoogle Scholar
  14. 14.
    Turner AM, Lin NI, Issarachai S, Lyman SD, Broudy VC. 1996. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 88:3383–3390.PubMedGoogle Scholar
  15. 15.
    Carter A, Haddad N, Draxler I, Israeli E, Raz B, Rowe JM. 1996. Expression and role in growth regulation of tumour necrosis factor receptors p55 and p75 in acute myeloblastic leukaemia cells. Br J Hematol 92:116–126.CrossRefGoogle Scholar
  16. 16.
    Khoury E, Andre C, Pontvert-Delucq S, Drenou B, Baillou C, Guigon M, Najman A, Lemoine FM. 1994. Tumor necrosis factor alpha (TNF alpha) downregulates c-kit protooncogene product expression in normal and acute myeloid leukemia CD34+ cells via p55 TNF alpha receptors. Blood 84:2506–2514.PubMedGoogle Scholar
  17. 17.
    Inoue K, Sugiyama H, Ogawa H, et al. 1994. Expression of the interleukin-6 (IL-6), IL-6 receptor, and gp130 genes in acute leukemia. Blood 84:2672–2680.PubMedGoogle Scholar
  18. 18.
    Lubbert M, Oster W, Knopf HP, McCormick F, Mertelsmann R, Herrmann F. 1993. N-RAS gene activation in acute myeloid leukemia: association with expression of interleukin-6. Leukemia 7:1948–1954.PubMedGoogle Scholar
  19. 19.
    Wagteveld AJ, Esselink MT, Limburg P, Halie MR, Vellenga E. 1992. The effects of IL-1 beta and IL-4 on the proliferation and endogenous secretion of growth factors by acute myeloblastic leukemic cells. Leukemia 6:1020–1024.PubMedGoogle Scholar
  20. 20.
    Liesveld JL, Keng PC, Rowe JM, et al. 1994. Effects of GM-CSF on Ki67 expression and cell cycle traverse in acute myelogenous leukemia specimens and cell lines. Leuk Res 18:609–616.PubMedCrossRefGoogle Scholar
  21. 21.
    Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulamn P, Lee EJ, Moore JO, Powell BL, Schiffer CA. 1995. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 332:1712–1735.CrossRefGoogle Scholar
  22. 22.
    Rowe JM, Andersen JW, Mazza JJ, et al. 1995. A randomized placebo-control study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86:457–462.PubMedGoogle Scholar
  23. 23.
    Heil G, Chadid L, Hoelzer D, Seipelt G, Mitrous P, Huber C, Kolbe K, Mertelsmann R, Lindemann A, Frisch J. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leuekmia (AML).Google Scholar
  24. 24.
    Harousseau JL, Wu D. 1995. The use of GM-CSF and G-CSF in the treatment of acute leukemias. Leuk Lymphoma 18:405–412.PubMedCrossRefGoogle Scholar
  25. 25.
    Ohno R. 1993. G-CSF in the treatment of acute myeloid leukemia: is it safe? Leuk Lymphoma 2:15–19.CrossRefGoogle Scholar
  26. 26.
    Büchner T, Hiddemann W, Koenigsmann M, et al. 1991. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78:1190–1197.PubMedGoogle Scholar
  27. 27.
    Estey EH, Thall P, Kantarjian S, et al. 1992. Treatment of newly-diagnosed acute myelogenous leukemia with granulocyte-macrophage colony stimulating factor (GM-CSF) before and during continuous-infusion high dose ara-C and daunorubicin: comparison to patients treated without GM-CSF. Blood 79:2246.PubMedGoogle Scholar
  28. 28.
    Geller RB. 1996. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol 14:1371–1382.PubMedGoogle Scholar
  29. 29.
    Griffin JD, Young D, Herrmann F, et al. 1986. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 67:1448–1453.PubMedGoogle Scholar
  30. 30.
    Lowenberg B, Touw IP. 1992. Haemopoietic growth factors in acute myeloblastic and lymphoblastic leukaemia. Baillieres Clin Haematol 5:599–618.PubMedGoogle Scholar
  31. 31.
    Sebban C, Archimbaud E, Coiffier B, et al. 1988. Treatment of acute myeloid leukemia in elderly patients. A retrospective study. Cancer 61:227–232.PubMedCrossRefGoogle Scholar
  32. 32.
    Yates J, Glidewell O, Wiernik P, et al. 1982. Cytosine-arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60:454–460.PubMedGoogle Scholar
  33. 33.
    Rees JK, Gray R. 1987. Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAT or MAZE consolidation therapy in the treatment of acute myeloid leukemia: MRC ninth AML trial. Semin Oncol 14(Suppl 1):32–36.PubMedGoogle Scholar
  34. 34.
    Preisler H, Davis RD, Kirshner J, et al. 1987. Comparison of three remission induction regimens and two post-induction strategies for the treatment of acute non-lymphocytic leukemia: a cancer and leukemia group B study. Blood 69:1441–1447.PubMedGoogle Scholar
  35. 35.
    Souza LM, Boone TC, Gabrilove J, et al. 1986. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232:61–64.PubMedCrossRefGoogle Scholar
  36. 36.
    Metcalf D. 1989. The roles of stem cell self-renewal and autocrine growth factor production in the biology of myeloid leuekmia. Cancer Res 49:2305.PubMedGoogle Scholar
  37. 37.
    Miyauchi J, Kelleher CA, Yang YC, et al. 1987. The effect of three recombinant growth factors, IL-3 GM-CSF and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood 70:657–662.PubMedGoogle Scholar
  38. 38.
    Vellenga E, Young DC, Wagner K, et al. 1987. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 69:1771–1776.PubMedGoogle Scholar
  39. 39.
    Büchner T, Hiddemann W, Zuhlstorf M, et al. 1988. Human recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment of patients with acute leukemias in aplasia and at high risk for early death. Blood 72:354.Google Scholar
  40. 40.
    Estey E, Dixon D, Kantarjian H, et al. 1990. Treatment of poor-prognosis, newly-diagnosed acute myeloid leukemia with Ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 75:1766–1772.PubMedGoogle Scholar
  41. 41.
    Zittoun R, Mandelli F, de Witt T, et al. 1994. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) during induction treatment of acute myelogenous leukemia (AML). A randomized trial from the EORTA-GIMEMA Leukemia Cooperative Groups. Blood 10(Suppl 1):909.Google Scholar
  42. 42.
    Witz F, Harousseau JL, Cahn JY. 1994. GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia (AML). Blood 84(Suppl 1):231.Google Scholar
  43. 43.
    Löwenberg B, Suciu S, Zittoun R, et al. 1995. GM-CSF during as well as after induction therapy (CT) in elderly patients with acute myeloid leukemia (AML). Blood 86(Suppl 1):433.Google Scholar
  44. 44.
    Baer MR, Christiansen NT, Frankel FS, et al. 1993. High-dose cytarabine, idarubicin and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia. Semin Oncol 20:6.PubMedGoogle Scholar
  45. 45.
    Estey EH. 1994. Use of colony-stimulating factors in the treatment of acute myeloid leukemia. Blood 83:2015–2019.PubMedGoogle Scholar
  46. 46.
    Dombret H, Chastand C, Fenaux P, et al. 1995. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678–1683.PubMedCrossRefGoogle Scholar
  47. 47.
    Ohno R, Naoe T, Kanamaru A, et al. 1994. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 83:2086–2091.PubMedGoogle Scholar
  48. 48.
    Godwin JE, Kopecky KJ, Head DR, et al. 1995. Double-blind, placebo-controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia. A Southwest Oncology Group Study. Blood 86:434.Google Scholar
  49. 49.
    Heil G, Hoelzer D, Sanz MA. 1995. Results of a randomized, double-blind, placebo-controlled Phase III study of filgrastim in remission induction and early consolidation therapy for adults with de novo acute myeloid leukemia. Blood 86(Suppl 1):267.Google Scholar
  50. 50.
    Dorr RT. 1993. Clinical properties of yeast-derived versus escherichia coli-derived granulocyte-macrophage colony-stimulating factor. Clin Ther 15:19–29.PubMedGoogle Scholar
  51. 51.
    Denzlinger C, Tetzloof W, Gerhartz HH, et al. 1993. Differential activation of the endogenous leukotriene biosynthesis by two different preparations of granulocyte-macrophage-colony-stimulating factor in healthy volunteers. Blood 81:2007–2013.PubMedGoogle Scholar
  52. 52.
    Rowe JM, Andersen J, Mazza JJ, et al. 1993. Phase III randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor (GM-CSF) in adult patients (55–70 years) with acute myelogenous leukemia (AML). Blood 82(Suppl 1):329.Google Scholar
  53. 53.
    Gadish M, Kletter Y, Fliedel O, et al. 1991. Effects of recombinant human granulocyte and granulocyte-macrophage colony-stimulating factors on the neutrophil function following autologous bone marrow transplantation. Leuk Res 15:1175–1182.PubMedCrossRefGoogle Scholar
  54. 54.
    Richardson MD, Brownlie CE, Shankland GS. 1992. Enhanced phagocytosis and intracellular killing of candida albicans by GM-CSF-activated human neutrophils. J Med Vet Mycol 30:433–441.PubMedCrossRefGoogle Scholar
  55. 55.
    Kowanko IC, Ferrante A, Harvey DP, et al. 1991. Granulocyte-macrophage colony-stimulating factor augments neutrophil killing of Torulopsis Gladrata and stimulates neutrophil respiratory burst and degranulation. Clin Exp Immunol 83:225–230.PubMedCrossRefGoogle Scholar
  56. 56.
    Levitz SM. 1991. Activation of human peripheral blood mononuclear cells by interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit cryptococcus neoformans. Infect Immun 59:3393–3397.PubMedGoogle Scholar
  57. 57.
    Nemunaitis J, Gordon A, Cox J, et al. 1994. Phase II pilot trial comparing neutrophil and monocyte function by microbial assay in oncology patients receiving rhG-CSF, rhGM-CSF, or no cytokine after cytotoxic chemotherapy. Blood 84(Suppl 1):37A. (abstract)Google Scholar
  58. 58.
    Smith PD, Lamerson CL, Banks SM, et al. 1990. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal for candida albicans. J Infect Dis 161:999–1005.PubMedGoogle Scholar
  59. 59.
    Wang M, Friedman H, Djeu JY. 1989. Enhancement of human monocyte function against candida albicans by the colony-stimulating factors (CSF): IL-3 granulocyte-macrophage-CSF, and macrophage-CSF. J Immunol 143:671–677.PubMedGoogle Scholar
  60. 60.
    Roilides E, Holmes A, Blake C, et al. 1994. Anti-fungal activity of elutriated human monocytes against aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma. J Infect Dis 170:894–899.PubMedGoogle Scholar
  61. 61.
    Abrahamsen TJ, Mertins S, Carter CS, et al. 1990. Negative impact of GM-CSF and IL-3 on the phagocytic capacity of monocytes. In: Proc XXXth ICAAC, A161.Google Scholar
  62. 62.
    Fabian I, Shapira E, Gadish M, et al. 1992. Effects of human interleukin-3, macrophage and granulocyte-macrophage colony-stimulating factor on monocyte function following autologous bone marrow transplantation. Leuk Res 16:703–709.PubMedCrossRefGoogle Scholar
  63. 63.
    Goordrich JM, Reed EC, Mori M, et al. 1991. Clinical features and analysis of risk factors for invasive candidal infection after bone marrow transplantation. J Infect Dis 164:731–740.Google Scholar
  64. 64.
    Rex JH, Bennett JE, Gallin JI, et al. 1991. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage aspergillus hyphae. J Infect Dis 163:849–854.PubMedGoogle Scholar
  65. 65.
    Ishizaka Y, Motoyoshi K, Hatake K, et al. 1986. Mode of action of human urinary colony-stimulating factor. Exp Hematol 8:1–8.Google Scholar
  66. 66.
    Motoyoshi K, Yoshida K, Hatake K, et al. 1989. Recombinant and native urinary colony-stimulating factor directly augments granulocyte and granulocyte-macrophage colony-stimulating factor production of human peripheral blood monocytes. Exp Hematol 17:68–71.PubMedGoogle Scholar
  67. 67.
    Hume DA, Denkins Y. 1992. The deleterious effect of macrophage colony-stimulating factor (CSF-1) on the pathology of experimental candidiasis in mice. Lymphokine Cytokine Res 11:95–98.PubMedGoogle Scholar
  68. 68.
    Bodey GP, Anaissie E, Gutterman J, et al. 1993. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infections in patients with cancer. Clin Infect Dis 17:705–707.PubMedGoogle Scholar
  69. 69.
    Nemunaitis J, Meyers JD, Buckner D, et al. 1991. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 78:907–913.PubMedGoogle Scholar
  70. 70.
    The International Chronic Granulomatous Disease Cooperative Study Group. 1991. A controlled trial of interferon-gamma to prevent infection in chronic granulomatous disease. N Engl J Med 324:509–515.CrossRefGoogle Scholar
  71. 71.
    Rowe JM, Rubin A, Mazza JJ. 1996. Incidence of infections in adult patients (>55 years) with acute myeloid leukemia treated with yeast-derived GM-CSF (sargramostin): results of double-blind prospective study by the Eastern Cooperative Oncology Group. In: Hiddemann W, Büchner T, Wörman B (eds), Acute Leukemias V: Experimental Approaches and Management of Refractory Diseases, pp 178–184.Google Scholar
  72. 72.
    Inatomi Y, Toyama K, Clark S. 1994. Combinations of stem cell factor with other hematopoietic growth factors enhance growth and sensitivity to cytosine arabinoside of blast progenitors in acute myelogenous leukemia. Cancer Res 54:455–462.PubMedGoogle Scholar
  73. 73.
    Reuter C, Auf eer Landwehr U, Schleyer U, et al. 1994. Modulation of intra-cellular metabolism in cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor. Leukemia 8:217–225.PubMedGoogle Scholar
  74. 74.
    Brach MA. 1991. To overcome pharmacologic and cytokinetic resistance to cytarabine in the treatment of acute myelogenous leukemia by using recombinant interleukin-3. Semin Hematol 4:39–46.Google Scholar
  75. 75.
    Büchner T, Hiddemann W, Rottmann R, et al. 1993. Multiple courses of chemotherapy with or without GM-CSF priming and long-term administration for newly-diagnosed AML. Proc M Natl Foc Clin Oncol 12:985.Google Scholar
  76. 76.
    Estey E, Thall P, Kantarjian H. 1992. Treatment of newly-diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose Ara-C plus daunorubicin: comparison to patients treated without GM-CSF. Blood 79:2246–2255.PubMedGoogle Scholar
  77. 77.
    Raza A, Maheshwari Y, Preisler HD. 1987. Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. Blood 69:1647–1653.PubMedGoogle Scholar
  78. 78.
    Riccardi A, Giordano M, Danova M, et al. 1991. Cell kinetics with in vivo bromodeoxyuridine and flow cytometry: clinical significance in acute non-lymphoblastic leukemia. Eur J Cancer 27:882–887.PubMedCrossRefGoogle Scholar
  79. 79.
    Clarkson B, Strife A, Fried J, et al. 1970. Studies of cellular proliferation in human leukemia. IV: Behavior of leukemic cells in three adults given continuous infusions of H3-Thymidine for 8 to 10 days. Cancer 25:1237–1260.PubMedCrossRefGoogle Scholar
  80. 80.
    Cannistra SA, DiCarlo J, Groshek P, et al. 1991. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 5:230–238.PubMedGoogle Scholar
  81. 81.
    Bettelheim P, Valent P, Andreeff M, et al. 1991. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction therapy in de novo acute myeloid leukemia. Blood 77:700–711.PubMedGoogle Scholar
  82. 82.
    Archimbaud E, Fenaux P, Reiffers J, et al. 1993. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia 7:371–377.Google Scholar
  83. 83.
    Frenette PS, Desforges JF, Schenkein DP, et al. 1995. Granulocyte macrophage colony-stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia. Am J Hematol 49:48–55.PubMedCrossRefGoogle Scholar
  84. 84.
    Aglietta M, De Feliz L, Stacchine A, et al. 1991. In vivo effect of granulocyte-macrophage colony-stimulating factor on the kinetics of human acute myeloid leukemia cells. Leukemia 5:979–984.PubMedGoogle Scholar
  85. 85.
    Takauji R, Tohyama K, Ueda T, Nakamura T. 1993. Enhancement of cytosine arabinoside cytotoxicity by granulocyte/macrophage colony-stimulating factor and granulocyte colony-stimulating factor in a human myeloblastic leukemia cell line. Jpn J Cancer Res 84:445–450.PubMedGoogle Scholar
  86. 86.
    Lotem J, Sachs L. 1989. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta-1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 80:1750–1757.Google Scholar
  87. 87.
    Estrov Z, Estey EH, Andreeff A, et al. 1992. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. Exp Hematol 20:558–564.PubMedGoogle Scholar
  88. 88.
    Valent P, Sillaber C, Geissler K, et al. 1992. Treatment of de novo acute myelogenous leukemia with recombinant granulocyte-macrophage colony-stimulating factor in combination with standard induction therapy: effect of GM-CSF on white blood cell counts. Med Pediatr Oncol Suppl 2:18–22.PubMedCrossRefGoogle Scholar
  89. 89.
    Estey E, Thall P, Andreeff M, et al. 1994. Use of granulocyte colony-stimulating factor before, during, and after fiudarabine plus cytarabine induction therapy of newly-diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fiudarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12:671–678.PubMedGoogle Scholar
  90. 90.
    Visanti G, Tosie P, Zinzani PL, et al. 1994. FLAG (Fiudarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of poor risk acute myeloid leukemias. Leukemia 8:1842–1846.Google Scholar
  91. 91.
    Yamada K, Furusawa S, Saito K, et al. 1995. Concurrent use of granulocyte-colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia 9:10–14.PubMedGoogle Scholar
  92. 92.
    Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O. 1995. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 85:2147–2153.PubMedGoogle Scholar
  93. 93.
    Peterson B, George K, Bhalla, et al. 1996. A phase III trial with or without GM-CSF administered before and during high dose cytarabine in patients with relapsed or refractory acute myelogenous leukemia (CALGB 9021). Proc Am Soc Clin Oncol (Suppl) 15:3.Google Scholar
  94. 94.
    Lotem J, Sachs L. 1984. Control of in vivo differentiation of myeloid leukemic cells. IV. Inhibition of leukemia development by myeloid differentiation-inducing protein. Br J Cancer 88:147.Google Scholar
  95. 95.
    Miyauchi J, Wang C, Kelleher C, et al. 1990. The effects of three recombinant growth factors, IL-3, GM-CSF, and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood 76:50.Google Scholar
  96. 96.
    Wang C, Kelleher C, Cheng G, et al. 1988. Expression of the CSF-1 gene in the blast cells of acute myeloblastic leukemia: association with reduced growth capacity. J Cell Physiol 135: 133.PubMedCrossRefGoogle Scholar
  97. 97.
    Selvakumaran M, Reed JC, Liebermann D, Hoffman B. 1994. Progression of the myeloid differentiation program is dominant to transforming growth factor-beta 1-induced apoptosis in M1 myeloid leukemic cells. Blood 84:1036–1042.PubMedGoogle Scholar
  98. 98.
    Takanashi M, Motoji T, Masuda M, Oshimi K, Mizoguchi H. 1993. The effects of leukemia inhibitory factor and interleukin 6 on the growth of acute myeloid leukemia cells. Leuk Res 17:217–222.PubMedCrossRefGoogle Scholar
  99. 99.
    Suzuki T, Bessho M, Hirashma K, Tohda S, Nagata K, Imai Y, Nara N. 1992. Interleukin-6 reduces the optimal growth in vitro of leukemic blast progenitors from acute myeloblastic leukemia patients. Acta Haematol 87:63–68.PubMedCrossRefGoogle Scholar
  100. 100.
    Givon T, Slavin S, Haran-Ghera N, Michalevicz R, Revel M. 1992. Antitumor effects of human recombinant interleukin-6 on acute myeloid leukemia in mice and in cell culture. Blood 79(9):2392–2398.PubMedGoogle Scholar
  101. 101.
    Estey E, Andreeff M. 1995. Phase II study of interleukin-6 in patients with smoldering relapse of acute myelogenous leukemia. Leukemia 9:1440–1443.PubMedGoogle Scholar
  102. 102.
    Lotem J, Sachs L. 1994. Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and bcl-2 dependent and independent pathways. Cell Growth Differ 5:321–327.PubMedGoogle Scholar
  103. 103.
    Giralt S, Escudier S, Kantarjian H, Deisseroth A, Freireich EJ, Andersson BS, O’Brien S, Andreeff M, Fisher H, Cork A. 1993. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 329:757–761.PubMedCrossRefGoogle Scholar
  104. 104.
    Ferrajoli A, Talpaz M, Zipf TF, Hirsch-Ginsberg C, Estey E, Wolpe SD, Estrov Z. 1994. Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha. Leukemia 8:798–805.PubMedGoogle Scholar
  105. 105.
    Carter A, Silvian-Draxler I, Tatarsky I. 1992. Effect of interleukin-1, tumor necrosis factor-alpha, and interferon-alpha on the blast cells of acute myeloblastic leukemia. Am J Hematol 40:245–252.PubMedCrossRefGoogle Scholar
  106. 106.
    Bruserud O, Tore Gjertsen B, Terje Brustugun O, Basoe CR, Nesthus I, Espen Akselsen P, Buhring HJ, Pawelec G. 1995. Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia. Leukemia 9:1910–1990.PubMedGoogle Scholar
  107. 107.
    Rogers SY, Bradbury D, Kozlowski R, Russell HN. 1994. Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Exp Hematol 22:593–598.PubMedGoogle Scholar
  108. 108.
    Russell NH. 1992. Autocrine growth factors and leukaemic haemopoiesis. Blood Rev 6:149–156.PubMedCrossRefGoogle Scholar
  109. 109.
    Russell NH, Hunter AE, Bradbury D, Zhu YM, Keith F. 1995. Biological features of leukaemic cells associated with autonomous growth and reduced survival in acute myeloblastic leukaemia. Leuk Lymphoma 16:223–229.PubMedCrossRefGoogle Scholar
  110. 110.
    Bradbury D, Zhu YM, Russell N. 1994. Regulation of Bcl-2 expression and apoptosis in acute myeloblastic leukaemia cells by granulocyte-macrophage colony-stimulating factor. Leukemia 8:786–791.PubMedGoogle Scholar
  111. 111.
    Cozzolino F, Rubartelli A, Aldinucci D, et al. 1989. Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells. Proc Natl Acad Sci USA 86:2369.PubMedCrossRefGoogle Scholar
  112. 112.
    Estrov Z, Kurzock R, Estey E, Wetzler M, Ferrajoli A, Harris D, Blake M, Gutterman JU, Talpaz M. 1992. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood 79:1938–1945.PubMedGoogle Scholar
  113. 113.
    Stosic-Grujicic S, Basara N, Milenkovic P, Dinarello CA. 1995. Modulation of acute myeloblastic leukemia (AML) cell proliferation and blast colony formation by antisense oligomer for IL-1 beta converting enzyme (ICE) and IL-1 receptor antagonist (IL-1ra). J Chemother 7:67–70.PubMedGoogle Scholar
  114. 114.
    Bradbury D, Rogers S, Reilly IA, Kozlowski R, Russell NH. 1992. Role of autocrine and paracrine production of granulocyte-macrophage colony-stimulating factor and interleukin-1 beta in the autonomous growth of acute myeloblastic leukaemia cells — studies using purified CD34-positive cells. Leukemia 6:562–566.PubMedGoogle Scholar
  115. 115.
    Delwel R, van Buitenen C, Salem M, et al. 1989. Interleukin-1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor. Blood 74:586.PubMedGoogle Scholar
  116. 116.
    Kaushansky K, Lin N, Adamson JW. 1988. Interleukin-1 stimulates fibroblasts to synthesize granulocyte-macrophage and granulocyte colony stimulating factors. J Clin Invest 81:92.PubMedGoogle Scholar
  117. 117.
    Bruserud O. 1996. Effects of endogenous interleukin 1 on blast cells derived from acute myelogenous leukemia patients. Leukemia Research 20:65–73.PubMedCrossRefGoogle Scholar
  118. 118.
    Zhu YM, Bradbury DA, Keith JF, Russell N. 1994. Absence of retinoblastoma protein expression results in autocrine production of interleukin-6 and promotes the autonomous growth of acute myeloid leukemia blast cells. Leukemia 8:1982–1988.PubMedGoogle Scholar
  119. 119.
    Murohashi I, Tohda S, Imai Y, Hirai Y, Nara N. 1993. Growth potentiating activity of endogenous production of interleukin-1 and tumor necrosis factor alpha in blast cells of acute myeloblastic leukemia. Exp Hematol 21:846–851.PubMedGoogle Scholar
  120. 120.
    Hunter AE, Rogers SY, Roberts IA, Barrett AJ, Russell N. 1993. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood 82:899–903.PubMedGoogle Scholar
  121. 121.
    Kurzrock R, Kantarjian H, Watzler M, Estrov Z, Estey E, Troutman-Worden K, Gutterman JU, Talpaz M. 1993. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. Exp Hematol 21:80–85.PubMedGoogle Scholar
  122. 122.
    Moreb J, Zucali JR, Rueth S. 1990. The effects of tumor necrosis factor-α on early human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide. Blood 76:681.PubMedGoogle Scholar
  123. 123.
    Moreb J, Zucali JR, Gross MA, et al. 1989. Protective effects of IL-1 on human hematopoietic progenitor cells treated in vitro with 4-hydroperoxycyclophosphamide. J Immunol 142:1937.PubMedGoogle Scholar
  124. 124.
    Estrov Z, Talpaz M, Estey EH, Strassmann G. 1995. Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferation. Exp Hematol 23:1080–1087.PubMedGoogle Scholar
  125. 125.
    Bhalla K, Holladay C, Arlin Z, et al. 1991. Treatment with IL-3 plus GM-CSF improves the selectivity of Ara-C in vitro against AML blasts. Blood 78:2674–2679.PubMedGoogle Scholar
  126. 126.
    Bhalla K, Ibradho AH, Bradt JE, Ray S, Huang Y, Tang C, Nawabi A. 1995. PIXY 3321 protects against ARAC or taxol-induced apoptosis and loss of clonogenic survival of normal human bone marrow progenitor cells. Leukemia 9:1851–1856.PubMedGoogle Scholar
  127. 127.
    Murohashi I, Endho K, Nishida S, Yoshida S, Jinnai I, Bessho M, Hirashima K. 1995. Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation. Exp Hematol 23:970–977.PubMedGoogle Scholar
  128. 128.
    Taetle R, Payne C, Dos Santos B, Russell M, Segarini P. 1993. Effects of transforming growth factor beta 1 on growth and apoptosis of human acute myelogenous leukemia cells. Cancer Res 53:3386–3393.PubMedGoogle Scholar
  129. 129.
    Broxmeyer HE, Cooper S, Hague N, Benninger L, Sarris A, Cornetta K, Vadhan-Raj S, Hendrie P, Mantel C. 1995. Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice. Ann Hematol 7:235–246.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1999

Authors and Affiliations

  • Jacob M. Rowe
  • Jane L. Liesveld

There are no affiliations available

Personalised recommendations